Finasteride is one of the two FDA-approved medications for male pattern hair loss, and it remains among the most studied treatments in dermatology. It does not regrow hair through stimulation alone; it addresses the hormonal mechanism driving follicle miniaturization in the first place. For men with androgenetic alopecia who are candidates for oral treatment, finasteride offers a targeted, evidence-backed option. Here is what the research actually shows and what men should realistically expect before starting.
What Causes the Hair Loss Finasteride Treats
Androgenetic alopecia is driven by dihydrotestosterone (DHT), a potent androgen derived from testosterone through the action of an enzyme called 5-alpha reductase. ( 1 ) In genetically susceptible men, DHT binds to receptors in scalp hair follicles at the temples and crown, triggering progressive miniaturization: the follicles shrink over successive hair cycles, producing progressively finer hairs until growth stops entirely.
The rate and extent of this process depends on both the level of DHT and the sensitivity of the follicular androgen receptors, which is genetically determined. ( 2 ) Finasteride works by targeting the enzymatic step that produces DHT rather than the receptor sensitivity itself, making it most effective for men in earlier stages of loss where follicles are still active.
How Finasteride Works
Finasteride selectively inhibits type II 5-alpha reductase, the isoform predominantly responsible for DHT production in the scalp and prostate. ( 3 ) By blocking this enzyme, finasteride significantly reduces serum DHT levels. Research published in the Journal of Clinical Endocrinology and Metabolism demonstrated that finasteride consistently reduced DHT levels in treated men, with scalp DHT levels falling substantially compared to baseline. ( 4 )
With lower DHT available to bind to follicular androgen receptors, the miniaturization process slows or halts. In follicles that have not yet become fully dormant, the reduced DHT environment allows some recovery of the anagen (growth) phase, which can result in visible regrowth over time.
Finasteride does not block testosterone itself; it shifts the testosterone-to-DHT conversion ratio. ( 5 ) Total testosterone levels typically remain within normal range, though some men experience a modest increase due to reduced conversion. If you are curious about how baseline hormone levels factor in, reviewing normal testosterone levels by age provides useful context.
What the Clinical Evidence Shows
The pivotal trials supporting finasteride’s approval for hair loss involved large placebo-controlled studies over two years. In a landmark trial published in the Journal of the American Academy of Dermatology, men taking finasteride showed a statistically significant increase in hair count compared to men taking placebo, with approximately 83% of treated men experiencing no further hair loss and about 66% showing visible improvement. ( 6 )
Long-term follow-up data extending to five years, published in the European Journal of Dermatology, confirmed that the benefits of finasteride are durable with continued use, with hair count and patient-reported satisfaction both remaining superior to placebo groups. ( 7 ) When men stop taking finasteride, the protective effect diminishes and hair loss typically resumes within 12 months.
Combining Finasteride with Minoxidil
Studies examining the combination of finasteride and topical minoxidil have shown greater improvements in hair density than either agent used alone. ( 8 ) Minoxidil acts through a different mechanism, prolonging the anagen phase and improving follicle vascularity, making the two treatments complementary rather than redundant.
What to Expect: Timeline and Results
Finasteride does not produce overnight results. The typical timeline is as follows:
Months 1 to 3: Hair loss slowing is the primary effect. Some men notice temporary increased shedding in the first few months as the hair cycle normalizes; this is generally not a sign that the medication is failing.
Months 3 to 6: Stabilization of hair loss becomes noticeable in most responders. Newly growing hairs may begin to emerge in previously thinning areas.
Months 6 to 12: Visible regrowth is most likely to become apparent in this window for men who will respond. Results continue to improve through 12 to 24 months of consistent use.
Response varies between individuals. Men with early-stage hair loss and active follicles tend to see greater benefit than those with long-established, advanced loss.
Common Myths About Finasteride
Myth: Finasteride will cause permanent sexual dysfunction. Post-marketing reports describe sexual side effects in a subset of men, including reduced libido and erectile changes. However, large-scale randomized trials reported these effects in a small percentage of participants, and the majority resolved upon discontinuation. ( 9 ) Men with concerns should discuss their full medical history with a prescribing physician.
Myth: You only need to take it for a year. Finasteride requires ongoing use to maintain results. Hair loss typically returns once treatment stops, as DHT production resumes.
Myth: Finasteride works the same for all men. Non-responders do exist. Genetic variation in 5-alpha reductase isoforms and androgen receptor sensitivity means individual response is not guaranteed. Evaluating progress at six to twelve months is a reasonable timeframe before reassessing.
Myth: Finasteride is unsafe for long-term use. Multi-year safety data from the Prostate Cancer Prevention Trial and other large studies have not shown significant long-term safety signals at the doses used for hair loss, though ongoing medical supervision is appropriate. ( 10 )
When to See a Doctor
Finasteride requires a prescription and should only be started after a physician evaluates your hair loss pattern, medical history, and any medications you are currently taking. It is not appropriate for women of childbearing potential and requires specific handling precautions.
Men already on testosterone replacement therapy should discuss finasteride with their prescribing physician, as the hormonal context of TRT may affect treatment considerations. Regular follow-up allows monitoring of both effectiveness and tolerability over time.
Is Finasteride Right for You?
If you are experiencing male pattern hair loss and want a treatment backed by decades of clinical data, finasteride is worth a serious conversation with a men’s health physician. The earlier you start, the more follicular activity there is to preserve. Book a consultation, have your pattern assessed, and get a clear picture of what to expect from treatment before your first dose.
Emergency Notice: If you or someone else is experiencing a medical emergency, call 911 immediately. The information on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
References
- Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186(4170):1213–1215. https://doi.org/10.1126/science.186.4170.1213
- Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Reviews in Molecular Medicine. 2002;4(22):1–11. https://doi.org/10.1017/S1462399402005112
- Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–441. https://doi.org/10.1016/S0090-4295(02)01905-2
- Rittmaster RS. Finasteride. New England Journal of Medicine. 1994;330(2):120–125. https://doi.org/10.1056/NEJM199401133300208
- Kaufman KD. Androgens and alopecia. Molecular and Cellular Endocrinology. 2002;198(1–2):89–95. https://doi.org/10.1016/S0303-7207(02)00372-5
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1998;39(4):578–589. https://doi.org/10.1016/S0190-9622(98)70007-6
- Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. Journal of the American Academy of Dermatology. 1999;40(6):930–937. https://doi.org/10.1016/S0190-9622(99)70081-1
- Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. Journal of Dermatology. 2002;29(8):489–498. https://doi.org/10.1111/j.1346-8138.2002.tb00310.x
- Traish AM, Hassani J, Guay AT, et al. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. Journal of Sexual Medicine. 2011;8(3):872–884. https://doi.org/10.1111/j.1743-6109.2010.02157.x
- Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine. 2003;349(3):215–224. https://doi.org/10.1056/NEJMoa030660